Endometriosis - Pipeline Review, Q1 2011
Global Markets Direct, February 2011, Pages: 39
Endometriosis - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'Endometriosis - Pipeline Review, Q1 2011', provides an overview of the Endometriosis therapeutic pipeline. This report provides information on the therapeutic development for Endometriosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Endometriosis. 'Endometriosis - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Endometriosis.
- A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Endometriosis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Endometriosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Endometriosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Endometriosis Overview
Therapeutics Development
An Overview of Pipeline Products for Endometriosis
Endometriosis Therapeutics under Development by Companies
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Endometriosis Therapeutics Development
Abbott Laboratories
Takeda Pharmaceutical Company Limited
Novartis AG
Gedeon Richter Plc.
Kissei Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Limited
Addex Pharmaceuticals
AEterna Zentaris Inc.
Soligenix, Inc.
Repros Therapeutics Inc.
Meditrina Pharmaceuticals, Inc.
Endometriosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Discontinued Products
Endometriosis - Featured News
1. Dec 27, 2010: Repros Completes Preclinical Studies Of Proellex
2. Dec 16, 2010: Repros Prepares To Begin Dosing In Second Cohort In Low Dose Proellex Study
3. Nov 22, 2010: Neurocrine Biosciences Successfully Completes Phase II Daisy PETAL Study With Elagolix
4. Jul 22, 2010: Repros Receives Investigational Review Board Approval To Commence Low Dose For Proellex Study At ICON Site
5. May 24, 2010: Neurocrine Biosciences Announces Positive Results From Daisy PETAL Study Of Elagolix
6. Apr 05, 2010: Repros Requests Lift Of Clinical Hold On Proellex
7. Feb 17, 2010: Soligenix Announces Issuance Of Hong Kong Patent For Its LPM Oral Drug Delivery Technology
8. Nov 24, 2009: Æterna Zentaris Announces Positive Results For Phase 2 Study With LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 In Endometrial Cancer
9. Oct 28, 2009: Repros Therapeutics Announces Amendment Of NIH Proellex License
10. Jul 29, 2009: Elagolix Announces Successful Six Month Lilac Petal Study.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Endometriosis, 2011
Products under Development for Endometriosis – Comparative Analysis, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Pre-Clinical Stage Development, 2011
Abbott Laboratories, 2011
Takeda Pharmaceutical Company Limited, 2011
Novartis AG, 2011
Gedeon Richter Plc., 2011
Kissei Pharmaceutical Co., Ltd., 2011
Teva Pharmaceutical Industries Limited, 2011
Addex Pharmaceuticals, 2011
AEterna Zentaris Inc., 2011
Soligenix, Inc., 2011
Repros Therapeutics Inc., 2011
Meditrina Pharmaceuticals, Inc., 2011
Assessment by Monotherapy Products, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products
List of Figures
Number of Products under Development for Endometriosis, 2011
Products under Development for Endometriosis – Comparative Analysis, 2011
Products under Development by Companies, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
